SurModics Purchases Additional Facility to Expand Brookwood Pharmaceuticals’ Development and Manufacturing Capacity
February  2008

EDEN PRAIRIE, Minnesota – April 23, 2008 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that its Brookwood Pharmaceuticals subsidiary, located in Birmingham, Alabama, has acquired an additional facility in the Birmingham area. This new facility will expand Brookwood’s capacity for research and development activities and clinical manufacturing in support of customer projects. Additionally, the building will be SurModics’ corporate center for commercial GMP manufacturing of drug delivery products for pharmaceutical and biotechnology customers.
read full release

Tipton Inducted in the AIMBE College of Fellows
February  2008

Birmingham, Alabama – February 21, 2008 – Arthur J. Tipton, Ph.D., President, Brookwood Pharmaceuticals, has been chosen as a new member of the College of Fellows by the American Institute for Medical and Biological Engineering (AIMBE). Tipton has been recognized for the development of biodegradable polymers and novel drug delivery systems. The induction ceremony is February 21, 2008.
read full release

SurModics Acquires Brookwood Pharmaceuticals: Strengthens Portfolio of Drug Delivery Technologies for the Pharmaceutical Industry
August  2007

EDEN PRAIRIE, Minnesota – August 1, 2007 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has acquired Brookwood Pharmaceuticals, Inc., a leading provider of drug delivery technology primarily to the pharmaceutical industry, from Southern Research Institute for $40 million in cash at closing and up to an additional $22 million in cash upon the successful achievement of specified milestones.
read full release

Carrington and Brookwood Pharmaceuticals Expand GelSite® Drug Delivery Technology Development
July 2007

July 20, 2007 - Carrington Laboratories, Inc. today announced that its subsidiary, DelSite Biotechnologies, Inc., extended a joint development agreement with Brookwood Pharmaceuticals, Inc. The goal of this effort is to continue an expanded evaluation of GelSite(R), a DelSite patented drug-delivery technology, as a matrix for injectable applications and for selected classes of drugs. This extension is built on the promising results and evaluations conducted by the joint technical team in the past year.
read full release

Brookwood Pharmaceuticals, Targeted Technology Ventures Form New Company to Improve Cardiac Stents
May 2007

Brookwood Pharmaceuticals, Inc. and Targeted Technology Ventures, LLC today announced the creation of a collaborative joint venture—Aeon Bioscience, Inc.—a company which will work to develop a new drug-eluting stent. The goal of the novel stent will be to overcome the current concerns of late stent thrombosis, or blood clot formation at or near the site of the stent and vessel closure due to formation of scar tissue, known as restenosis. Brookwood Pharmaceuticals is a Birmingham-based drug-delivery company. Targeted Technology Ventures (TTV) is a San Antonio-based biotechnology and medical device company. Series A funding was secured through the Birmingham Technology Fund, managed by Greer Capital Advisors LLC of Birmingham. Aeon Bioscience will be headquartered in Birmingham.
read full release

elbion Acquires Late-Stage Product Candidate for Treatment of Alcohol Dependence 
January 2007

elbion NV, a leading European drug discovery and development company, today announced it has acquired a number of product candidates from the French biotechnology company DrugAbuse Sciences. The most advanced candidate, Naltrexone Depot, a sustained release formulation of naltrexone, will become elbion’s lead product and the company expects it to enter pivotal Phase III clinical trials in 2007. A second asset acquired is Buprenorphine Depot, a sustained release buprenorphine indicated for the treatment of opiate addiction. 
read full release

Lakeshore Biomaterials Announces New Polymer Products  
January 2007

BIRMINGHAM, ALABAMA– January, 2007 – Lakeshore Biomaterials announces a new catalog of polymer products with a simplified naming system.
more information

Secrist Named CEO of Southern Research Institute
September 2006

John A. “Jack” Secrist III, Ph.D. has been named president and CEO of Southern Research Institute following a national search, said UAB President and Southern Research Board chair Dr. Carol Z. Garrison. His appointment is effective Sept. 18. 
read full release

New Director of Quality 
August 2006

Brookwood Pharmaceuticals welcomes Robert J. Brady as the Director of Quality.  “We are pleased to welcome Bob to our team,” says Arthur J. Tipton, PhD, CEO and President.  “He adds a wealth of experience and is a definite asset for the growing quality group at Brookwood Pharmaceuticals”. 
read full release

Carrington and Brookwood Pharmaceuticals Expand GelSite® Drug Delivery Technology Development
July 2006

July 20, 2006 - Carrington Laboratories, Inc. (NASDAQ:  CARN) announced today that its subsidiary, DelSite Biotechnologies, Inc., formed a joint development initiative with Brookwood Pharmaceuticals, Inc.
read full release

Genzyme Pharmaceuticals and Brookwood Pharmaceuticals Enter Broad Collaboration in Drug Delivery 
May 2006

May 1, 2006 - Genzyme Pharmaceuticals, a business unit of Genzyme Corporation, and Brookwood Pharmaceuticals, Inc., today announced a broad collaboration to develop novel drug delivery solutions.
read full release

Brookwood Pharmaceuticals, Scientific Advisory Board Convenes 
April 2006

April 25, 2006 - Brookwood Pharmaceuticals' Scientific Advisory Board convened for the first time.
read full release

Lakeshore Biomaterials Names New Executives
May 2005

Lakeshore Biomaterials today named two new executives to its staff in Birmingham. Joining Lakeshore are Paul Spencer and John Middleton.
read full release

SRI Spins off drug group
January 2005

"They're going to have some dramatic opportunities for developing new pharmaceuticals and I can't think of a better way to get a company under way," said Mike Alder, director the Biotechnology Association of Alabama.
read full release.

Brookwood Pharmaceuticals acquires the polymer business of Alkermes, Inc.
January 2005

Alkermes and Lakeshore Biomaterials are committed to produce a seamless transition of the polymer business, with the quality and service you've come to expect from the Alkermes Medisorb® polymer business.
read full release


Contact information:

Brookwood Pharmaceuticals
756 Tom Martin Drive
Birmingham, AL 35211
phone 205.917.2200
fax 205.917.2205
Or visit our Contact Page.